No takeover bids have been received for the biopharmaceutical company Lysogene, which had set an April 12 deadline for the submission of potential bids.

The company, which specializes in gene therapies targeting central nervous system disorders, was seeking to acquire a stake in Lysogene as part of the receivership proceedings opened by the courts in January.

The Nanterre Commercial Court is now expected to rule on the follow-up to be given to the receivership proceedings, and on the possible opening of a compulsory liquidation procedure in the coming weeks.

In this context, trading in Lysogene shares will remain suspended, as has been the case since January 5.

Copyright (c) 2023 CercleFinance.com. All rights reserved.